Takker for svaret!
Greit at du understreker at det er din subjektive oppfatning, men det er likevel noe betryggende over det å få høre dette fra noen som er tilstede i egen person, spesielt også når det kommer fra en som jeg anser som meget troverdig og kunnskapsrik.
4 Likes
Noe du vil eller kan utdype her?
Takker for den FiloD
FiloD
“Jeg fikk også en meget klar følelse at fimaVacc resultatene er meget gode, her virket de enormt sikre. Og ja, det er mitt klare intrykk at de snakker med partnere, både BP og mindre special selskaper innenfor sektoren, derfor er det kun spørgsmål om tid før vi ser avtaler (det er selfølgelig min egen subjektive mening)”
Me;
Fin informasjon til oss som ikke var der.
3 Likes
I episode 3 i podcasten til radforsk så nevner PW thailand hvor han oppgir 80 ganger flere som får GGK sammenlignet med vesten.
2 Likes
Det kan vaere ett signal…
2 Likes
Nei, desværre. 
Har utrolig høye forventninger til vacc og nac. Tror markedet ikke er informert om mulighetene som ligger her unntatt de dedikerte på forum og spesialinvestorer. Tror også at CEO-er gir hint både om det ene og det andre.
4 Likes
Mulig partneravtale Q1 2019, meget gode fimaVacc resultater etc…håper dine subjektive synsinger stemmer, FiloD 
2 Likes
Det er vel en del som følger med på partneres utvikling?
I den forbindelse kan det være greit å vite at RXII har byttet navn og ticker:
4 Likes
Klippet fra
http://pcibiotech.no/partnering/
Alliances and partnering opportunities
PCI Biotech is an oncology-focused company developing innovative products for cancer treatment. The products are based on PCI Biotech’s patented technology, photochemical internalisation (“PCI”). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules such as RNA therapeutics to reach intracellular targets. Our objective is to deliver value to cancer patients through the development of products within three major anticancer treatment paradigms:
- fima CHEM – Enhancement of existing therapeutics for localised treatment of cancer, for indications with a clear unmet medical need; pivotal phase II ready opportunity in an orphan cancer indication, cholangiocarcinoma (bile duct cancer).
- fima VACC – Novel mechanism of action of the PCI technology to be used as a CTL induction technology for therapeutic and prophylactic vaccination with potential value creation in both cancer and infectious diseases; phase I in healthy volunteers initiated.
- fima NAc – Novel delivery Technology for pharmaceutical and biotechnology companies looking to overcome the challenge of introducing nucleic acid therapeutics into cells; preclinical programme.
To fully exploit the potential of our three major PCI applications, we are looking for partnerships with renowned pharmaceutical and biotech Companies.
Together, we will unlock the potential of your drug candidates. We continue to commit to partners with synergistic ideas to develop innovative drug candidates.
Partners should share our vision to develop and commercialize the next generation of anti-cancer therapeutics.
Collaborations
PCI Biotech has an excellent track record in its partnering activities. These successful scientific collaborations are not only contributing towards the validation of Our technology platform but are also bringing value to our partners.
Where to meet us:
List of all events where we are planning to attend during current half year, with a link to the event:
- ESMO Immuno-Oncology Congress, Geneva, December 13-16, 2018
- Biotech Showcase, San Francisco, January 7-9, 2019
5 Likes
PCI Biotech has an excellent track record in its partnering activities. These successful scientific collaborations are not only contributing towards the validation of Our technology platform but are also bringing value to our partners.
Det må kunne sies at dette er bull statement?
4 Likes
Fint hvis det blir litt value til PCIB også etterhvert, i form av oppstart klinisk program, utvidede og nye partneravtaler, og kanskje noen millioner ekstra i kassen også.
Blir ikkje excellent før noe av dette er på plass. Til nå er det bare promising.
Lothian
2 Likes
Ikke lite promising heller om en leser mellom linjene?!
Alt til en liten neve dollars
Pci biotech is under presenting companies for this event.
http://events.ebdgroup.com/bts/core/presenting-companies.php?topic=presenting+company+(public)
presenting public companies in this event (including pci biotech) are allowed 30 minutes presentation, while private companies can present for maximum 15 minutes
24 Likes
Industry
Global Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025
Innovate Insights Innovate Insights 2 hours ago 0 0
Innovate Insights Market Research recently published Global Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 Market Research study which offers insights of in-depth research on historic and current market size along with the expected future prospects of the market and emerging trends in the market. Global Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 Market 2018 research report further delivers the methodical outlook of the industry by considering features such as Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 market growth, consumption volume, market trends and Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 industry cost structure during the forecast period 2018-2025.
Get Free Sample Copy of Report Here: https://www.innovateinsights.com/report/global-cellular-tumor-antigen-p53market-2018-manufacturers/16477/#requestsample
Features of Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 Market Research Report as below:
Top manufacturers operating in the Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 market: Advaxis, Inc., American Gene Technologies International Inc., Aprea AB, Cellceutix Corporation, Critical Outcome Technologies Inc., Eleos Inc., ORCA Therapeutics B.V., OSE Pharma SA, PCI Biotech Holding ASA, Quark Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Shenzen SiBiono GeneTech Co., Ltd., SK Biopharmaceuticals Co., Ltd., Tara Immuno-Oncology Therapeutics LLC, Z53 Therapeutics, LLC
Market Segment by Type, covers: COTI-2, D-12PGJ3, APR-246, ATRN-502, Cenersen Sodium, MJ-05, MX-225, Others
Market Segment by Applications, can be divided into: Ovarian Cancer, Prostate Cancer, Brain Cancer, Others
The introductory section of the report offers global Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 market overview including objectives of Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 research, definition and specifications. Further, this is followed by broad section on Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 market scope and size evaluation with respect to regional production analysis and the expected CAGR for the period 2018 to 2025. This detailed study develops Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 market concentration ratio and strategies of Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 business. Further report covers a diverse range of elements such as Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 trend analysis, investment return and feasibility analysis, new project SWOT analysis which helps to analyze the competitive player’s growth in the Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 industry.
Inquire Before Buying @ https://www.innovateinsights.com/report/global-cellular-tumor-antigen-p53market-2018-manufacturers/16477/#buyinginquiry
Global Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 market is segmented based on product type, applications along with geographical fragmentation including the regions India, Japan, South East Asia, Europe, China and USA. This section offers major aspects including region-wise production capacity, price, demand, supply chain/logistics, profit/loss, material parameters/specifications, consumption, export/import details, growth rate from 2013 to 2018, and market structure.
This following section highlights a comprehensive company profiling of top manufacturers operating in the market. This section provides information about leading players with their useful business strategies in the market. The company analysis offers company description, product picture and specification, financial overview (such as annual revenue, Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 production and sales value) and the recent key developments. This section is measured as the fundamental part of the Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 market report which emphasis on current market trends and intended development associated with dominating market players.
About Us:
Innovate Insights is a large market research firm that has more than just syndicated market research report for the clienteles. Slipping into your shoes, we will be more than happy to serve your need from your point of view. We don’t pigeonhole our services and provide customized research services, market advisors, market consultants, market research reports and so much more. Our team is built with research specialists, market research trackers and market research coordinators in each industry vertical.
4 Likes
Top manufacturers operating in the Cellular Tumor Antigen p53 Market 2018 – Manufacturers, Types and Application, Analysis History and Forecast 2025 market: Advaxis, Inc., American Gene Technologies International Inc., Aprea AB, Cellceutix Corporation, Critical Outcome Technologies Inc., Eleos Inc., ORCA Therapeutics B.V., OSE Pharma SA, PCI Biotech Holding ASA, Quark Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Shenzen SiBiono GeneTech Co., Ltd., SK Biopharmaceuticals Co., Ltd., Tara Immuno-Oncology Therapeutics LLC, Z53 Therapeutics, LLC
Hvor er det PCI Biotech nå ikke regnes med?
2 Likes
Olivecrona er garantert en stor verdi for PCIB.
Gleder meg til å se hva han får (har fått) til med teamet.
PCI Biotech appoints Dr Hans Olivecrona as Chief Medical Officer
Email Print Friendly Share
August 23, 2017 02:00 ET | Source: PCI Biotech Holding
Oslo (Norway), 23 August 2017 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company is pleased to announce the appointment of Dr. Hans Olivecrona MD PhD as Chief Medical Officer (CMO). Dr Olivecrona will also serve as a member of PCI Biotech’s executive management team. He will lead the execution of all clinical development programmes, and be a key contributor to the identification and implementation of new opportunities and pipeline expansions.
Dr Olivecrona brings extensive experience in the development and commercialisation of novel therapeutics. In his most recent role, Dr. Olivecrona held the position as Senior Medical Director at Swedish Orphan Biovitrum (Sobi AB) in Stockholm, Sweden, with the responsibility for medical affairs and all medical aspects of business development for Sobi’s international partner product portfolio. Prior to this, Dr Olivecrona held various positions spanning from preclinical and clinical development to regulatory interactions. Dr Olivecrona has a PhD from the Karolinska Institute and his work experience includes 20 years of academic clinical background, mainly within oncological surgery with a specialty in gastrointestinal cancers. Dr Olivecrona also headed a hospital research facility and is the author of numerous scientific publications.
Per Walday, CEO, comments: "We are delighted to welcome Dr Olivecrona to PCI Biotech. With his broad scientific, clinical and business development background he will bring important knowhow and experience to our organisation, as we move towards a potential pivotal development phase for our lead programme fimaChem. "
Dr Hans Olivecrona added: “I am very excited to be joining PCI Biotech at what is clearly an important stage for the company. The encouraging fimaChem Phase I data in inoperable perihilar bile duct cancer may pave the way for expedited development and market entrance to the benefit of this underserved patient population. I am also very much looking forward to working on the development of the exciting fimaVacc and fimaNac assets.”
2 Likes